Volume 29, Number 6—June 2023
Research
SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022
Lauren E. Bloomfield, Sera Ngeh, Gemma Cadby, Kate Hutcheon, and Paul V. Effler
Table 6
Dosing schedule for case-patients and controls included in the heterologous versus homologous 3-dose vaccination schedule analysis of SARS-CoV-2 vaccine effectiveness, Western Australia, Australia, February 1, 2022–May 31, 2022*
| Dose 1 | Dose 2 | Dose 3 | No. (%) |
|---|---|---|---|
| Homologous 3-dose vaccination schedules | |||
| BNT162b2 mRNA | BNT162b2 mRNA | BNT162b2 mRNA | 112,939 (75.7) |
| BNT162b2 mRNA | BNT162b2 mRNA | mRNA-1273 | 30,676 (20.6) |
| mRNA-1273 | mRNA-1273 | mRNA-1273 | 3,721 (2.5) |
| mRNA-1273 | mRNA-1273 | BNT162b2 mRNA | 1,775 (1.2) |
| mRNA-1273 | BNT162b2 mRNA | BNT162b2 mRNA | 22 (0) |
| mRNA-1273 | BNT162b2 mRNA | mRNA-1273 | 9 (0) |
| BNT162b2 mRNA | mRNA-1273 | mRNA-1273 | 7 (0) |
| BNT162b2 mRNA |
mRNA-1273 |
BNT162b2 mRNA |
2 (0) |
| Heterologous 3-dose vaccination schedules | |||
| ChAdOx1 | ChAdOx1 | BNT162b2 mRNA | 18,925 (78.2) |
| ChAdOx1 | ChAdOx1 | mRNA-1273 | 5,261 (21.8) |
*BNT162b2, Pfizer-BioNTech (https://www.pfizer.com); ChAdOx1, AstraZeneca (https://www.astrazeneca.com); mRNA-1273, Moderna (https://www.modernatx.com).
Page created: April 19, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.